Tag: Kinase inhibitor

Tukysa, a targeted therapy approved by the FDA in 2020 for certain HER2-positive cancers, is more formally known by its generic name, tucatinib. This oral medication works as a kinase inhibitor to block signaling pathways that promote cancer cell growth, and it is crucial for patients and clinicians to understand its multiple identifiers for accurate treatment management.

Originally approved by the FDA in 2012 for metastatic colorectal cancer, a key question for patients and caregivers is, What is another name for Regorafenib? The answer is its brand name, Stivarga, an oral multi-kinase inhibitor developed by Bayer.

Regorafenib, a potent oral multi-kinase inhibitor, leverages a distinct and multi-pronged approach to inhibit cancer progression by targeting multiple signaling pathways critical for tumor growth, angiogenesis, and metastasis. Unlike traditional cytotoxic chemotherapy, its unique mechanism of action focuses on blocking specific proteins, providing a targeted therapeutic effect.

First receiving accelerated approval from the FDA in 2020 for certain bile duct cancers, the specialized targeted therapy Pemazyre prompts the question: **Who is the manufacturer of pemigatinib?** The answer is Incyte Corporation, a global biopharmaceutical company focusing on the discovery, development, and commercialization of proprietary therapeutics.

In 2020, selumetinib received FDA approval as the first effective treatment for children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). But beyond its clinical success, a critical question remains: **how does selumetinib work** at a molecular level to produce these therapeutic effects?

In a phase III clinical trial for radioactive iodine-refractory thyroid cancer, 100% of lenvatinib-treated patients experienced at least one adverse event, highlighting the importance of understanding **what are the side effects of lenvatinib?**. Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor used to treat various cancers, including thyroid, kidney, and liver cancer.

Sorafenib, a multikinase inhibitor also known by the brand name Nexavar®, was one of the first targeted therapies to demonstrate a significant survival benefit in patients with advanced hepatocellular carcinoma. This oral medication is primarily used to treat three distinct types of advanced cancer: liver, kidney, and a specific type of thyroid carcinoma.

Pazopanib, marketed under the brand name Votrient, has demonstrated significant efficacy in treating specific types of advanced cancers. Approved by the U.S. Food and Drug Administration (FDA) for both advanced renal cell carcinoma and advanced soft tissue sarcoma, this medication is a powerful component of targeted therapy regimens.